Drugs / Fragment Autoantigens Stimulated T-Cell-Immunotherapy
Fragment Autoantigens Stimulated T-Cell-Immunotherapy
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06756295 | Mar 2025 → Mar 2028 expected | colorectal cancer, lung cancer, melanoma | Fengming Kong | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fragment Autoantigens Stimulated T-Cell-Immunotherapy | “Fragment Autoantigens Stimulated T-Cell-Immunotherapy (FAST) as a Fast Autologous Cancer Vaccine.” PMID 40135850 ↗ Mar 2025 |
| Known as | FAST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06756295 ↗ |
| Known as | Fragmented Autoantigen Stimulated T-cell Immunotherapy | “Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.” NCT06756295 ↗ |
| Modality | Vaccine | “a personalized whole tumor cell vaccine (TCV), termed fragment autoantigens stimulated T-cell-immunotherapy (FAST) is developed.” PMID 40135850 ↗ Mar 2025 |